Preferencias de las usuarias colombianas en cuanto al uso de anticonceptivos orales. Estudio descriptivo

Combined oral contraceptives have evolved rapidly in recent decades to reduce side effects without affecting the efficacy and according to the preferences of women. It is important to understand the perceptions and expectations of users to improve adherence and reduce the failure of contraception. To this end we conducted a survey-based study within a sample of 389 users aged 18 and 45 years of age in 4 major cities of Colombia, to assess sociodemographic variables in addition to knowledge and preferences of users related to the additional benefits of this contraceptive therapy. The sample consisted mostly of women belonging to middle (62.7%) and high (37.3%) socioeconomic groups. 40.9% of participants were in the group of 18 to 25 years, 43.0% in the group of 26 to 35 years and 16.1% in the group of 36 to 45 years. 58.4% of participants reported knowing at least one additional benefit of oral contraceptives, and when they were asked to rank by importance five attributes proposed by the interviewer as potential beneficial effects was obtained for all age groups the following order: 1) that it does not affect body weight (35.2%), 2) reduction of dysmenorrhea (26.6%), 3) improve the quality of the skin (20.1%), 4) decrease in duration and volume of menstrual bleeding (13.3%) and 5) reduce mood fluctuations (5%). An individualized and comprehensive contraceptive counseling, which assesses the prior knowledge of the potential beneficial effects of oral contraceptives, expectations and preferences of users will contribute to reducing unplanned pregnancy rates associated with incorrect use or with early discontinuation of therapy

Preferencias de las usuarias colombianas en cuanto al uso de anticonceptivos orales. Estudio descriptivo

Combined oral contraceptives have evolved rapidly in recent decades to reduce side effects without affecting the efficacy and according to the preferences of women. It is important to understand the perceptions and expectations of users to improve adherence and reduce the failure of contraception. To this end we conducted a survey-based study within a sample of 389 users aged 18 and 45 years of age in 4 major cities of Colombia, to assess sociodemographic variables in addition to knowledge and preferences of users related to the additional benefits of this contraceptive therapy. The sample consisted mostly of women belonging to middle (62.7%) and high (37.3%) socioeconomic groups. 40.9% of participants were in the group of 18 to 25 years, 43.0% in the group of 26 to 35 years and 16.1% in the group of 36 to 45 years. 58.4% of participants reported knowing at least one additional benefit of oral contraceptives, and when they were asked to rank by importance five attributes proposed by the interviewer as potential beneficial effects was obtained for all age groups the following order: 1) that it does not affect body weight (35.2%), 2) reduction of dysmenorrhea (26.6%), 3) improve the quality of the skin (20.1%), 4) decrease in duration and volume of menstrual bleeding (13.3%) and 5) reduce mood fluctuations (5%). An individualized and comprehensive contraceptive counseling, which assesses the prior knowledge of the potential beneficial effects of oral contraceptives, expectations and preferences of users will contribute to reducing unplanned pregnancy rates associated with incorrect use or with early discontinuation of therapy

Efficacy and safety of administering oral misoprostol by titration compared to vaginal misoprostol and dinoprostone for cervical ripening and induction of labour: study protocol for a randomised clinical trial

Abstract Background Among the various methods available, the administration of prostaglandins is the most effective for inducing labour in women with an unfavourable cervix. Recent studies have compared treatment with various titrated doses of oral misoprostol with vaginal misoprostol or dinoprostone, indicating that the use of an escalating dose of an oral misoprostol solution is associated with a lower rate of caesarean sections and a better safety profile. The objective of this study is to assess which of these three therapeutic options (oral or vaginal misoprostol or vaginal dinoprostone) achieves the highest rate of vaginal delivery within the first 24 h of drug administration. Methods An open-label randomised controlled trial will be conducted in Araba University Hospital (Spain). Women at ≥41 weeks of pregnancy requiring elective induction of labour who meet the selection criteria will be randomly allocated to one of three groups: 1) vaginal dinoprostone (delivered via a controlled-release vaginal insert containing 10 mg of dinoprostone, for up to 24 h); 2) vaginal misoprostol (25 μg of vaginal misoprostol every 4 h up to a maximum of 24 h); and 3) oral misoprostol (titrated doses of 20 to 60 μg of misoprostol following a 3 h on + 1 h off regimen up to a maximum of 24 h). Both intention-to-treat analysis and per-protocol analysis will be performed. Discussion The proposed study seeks to gather evidence on which of these three therapeutic options achieves the highest rate of vaginal delivery with the best safety profile, to enable obstetricians to use the most effective and safe option for their patients. Trial registration NCT02902653 Available at: https://clinicaltrials.gov/show/NCT02902653 (7th September 2016)